(Reuters) – Walmart (NYSE) Inc. and CVS Health Corp. (NYSE) announced Wednesday that they would no longer fill prescriptions for controlled substances from telehealth startup Cerebral Inc. and Done Health.

Cerebral & Done have a reputation for prescribing stimulants to ADHD patients.

Walmart has confirmed that the Walmart move was being made to Reuters. They said it had been done after an audit and compliance review.

CVS announced that it would not accept controlled substance prescriptions from startups starting May 26. This was in response to a review of the telehealth companies and “unable” to address concerns it has with Cerebral Health.

Cerebral and Done have not responded to Reuters’ requests for comment.

The Wall Street Journal reported that Cerebral received a subpoena earlier this month by federal prosecutors in an investigation of possible violations to the Controlled Substances Act.